Intercept Pharmaceuticals (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Intercept Pharmaceuticals" in English language version.

refsWebsite

Global rank English rank

4interceptpharma.com

low place

3web.archive.org

1^st place

2yahoo.com

38^th place

40^th place

1macrotrends.net

5,641^st place

4,405^th place

1fda.gov

447^th place

338^th place

1europa.eu

68^th place

117^th place

1pharmaceutical-technology.com

low place

1statnews.com

8,771^st place

5,253^rd place

1seekingalpha.com

5,344^th place

3,420^th place

1clinicaltrial.gov

low place

1reuters.com

49^th place

47^th place

1biospace.com

low place

7,595^th place

biospace.com (Global: low place; English: 7,595^th place)

"Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs". On Tuesday, still reeling from the rejection and left with no other advanced assets, Intercept agreed to be acquired by Italian pharma Alfasigma S.p.A for $800 million.

clinicaltrial.gov (Global: low place; English: low place)

"The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)". Archived from the original on 2014-01-10.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"EMA recommends revoking conditional marketing authorisation for Ocaliva | European Medicines Agency (EMA)". www.ema.europa.eu. 2024-06-28. Retrieved 2025-02-06.

fda.gov (Global: 447^th place; English: 338^th place)

Research, Center for Drug Evaluation and (2020-07-09). "Drug Trials Snapshots: OCALIVA". FDA.

interceptpharma.com (Global: low place; English: low place)

ir.interceptpharma.com

Intercept Pharma. "Press release: Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology". Archived from the original on November 29, 2014. Retrieved January 9, 2014.
Intercept Pharma. "Press release: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results". Archived from the original on March 26, 2014. Retrieved March 27, 2014.
Intercept Pharmaceuticals. "Form 10-k: Annual report 2014". Retrieved October 2, 2015.

interceptpharma.com

"Contact Us". Intercept Pharmaceuticals. Retrieved 13 April 2022.

macrotrends.net (Global: 5,641^st place; English: 4,405^th place)

"Intercept Pharmaceuticals Revenue 2011-2021 | ICPT".

pharmaceutical-technology.com (Global: low place; English: low place)

Barrie, Robert (2024-11-13). "Intercept loses Ocaliva FDA full approval bid in rare liver disease". Pharmaceutical Technology. Retrieved 2025-02-06.

reuters.com (Global: 49^th place; English: 47^th place)

"Intercept's liver disease drug proves highly effective in study". Reuters. April 12, 2014. Retrieved April 14, 2014.

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

"Intercept Pharmaceuticals: Strong Biopharmaceutical IPO". Seeking Alpha. October 14, 2012. Retrieved 2014-03-21.

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

"FDA rejects Intercept Pharma's drug for fatty liver disease". 29 June 2020.

web.archive.org (Global: 1^st place; English: 1^st place)

"The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)". Archived from the original on 2014-01-10.
Intercept Pharma. "Press release: Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology". Archived from the original on November 29, 2014. Retrieved January 9, 2014.
Intercept Pharma. "Press release: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results". Archived from the original on March 26, 2014. Retrieved March 27, 2014.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases". Yahoo Finance. 2023-09-26. Retrieved 2023-09-26.
"Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc". Yahoo! Finance. Retrieved 2024-01-07.

Intercept Pharmaceuticals (English Wikipedia)

biospace.com (Global: low place; English: 7,595th place)

clinicaltrial.gov (Global: low place; English: low place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

interceptpharma.com (Global: low place; English: low place)

ir.interceptpharma.com

interceptpharma.com

macrotrends.net (Global: 5,641st place; English: 4,405th place)

pharmaceutical-technology.com (Global: low place; English: low place)

reuters.com (Global: 49th place; English: 47th place)

seekingalpha.com (Global: 5,344th place; English: 3,420th place)

statnews.com (Global: 8,771st place; English: 5,253rd place)

web.archive.org (Global: 1st place; English: 1st place)

yahoo.com (Global: 38th place; English: 40th place)

finance.yahoo.com

biospace.com (Global: low place; English: 7,595^th place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

macrotrends.net (Global: 5,641^st place; English: 4,405^th place)

reuters.com (Global: 49^th place; English: 47^th place)

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

web.archive.org (Global: 1^st place; English: 1^st place)

yahoo.com (Global: 38^th place; English: 40^th place)